Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor
Chunhui Jiang, … , Chao Xing, Lu Q. Le
Chunhui Jiang, … , Chao Xing, Lu Q. Le
Published May 4, 2023
Citation Information: J Clin Invest. 2023;133(12):e168227. https://doi.org/10.1172/JCI168227.
View: Text | PDF
Research Article Oncology

Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor

  • Text
  • PDF
Abstract

Neurofibromatosis type 1 (NF1) is one of the most common tumor-predisposing genetic disorders. Neurofibromas are NF1-associated benign tumors. A hallmark feature of neurofibromas is an abundant collagen-rich extracellular matrix (ECM) that constitutes more than 50% of the tumor dry weight. However, little is known about the mechanism underlying ECM deposition during neurofibroma development and treatment response. We performed a systematic investigation of ECM enrichment during plexiform neurofibroma (pNF) development and identified basement membrane (BM) proteins, rather than major collagen isoforms, as the most upregulated ECM component. Following MEK inhibitor treatment, the ECM profile displayed an overall downregulation signature, suggesting ECM reduction as a therapeutic benefit of MEK inhibition. Through these proteomic studies, TGF-β1 signaling was identified as playing a role in ECM dynamics. Indeed, TGF-β1 overexpression promoted pNF progression in vivo. Furthermore, by integrating single-cell RNA sequencing, we found that immune cells including macrophages and T cells produce TGF-β1 to induce Schwann cells to produce and deposit BM proteins for ECM remodeling. Following Nf1 loss, neoplastic Schwann cells further increased BM protein deposition in response to TGF-β1. Our data delineate the regulation governing ECM dynamics in pNF and suggest that BM proteins could serve as biomarkers for disease diagnosis and treatment response.

Authors

Chunhui Jiang, Ashwani Kumar, Ze Yu, Tracey Shipman, Yong Wang, Renee M. McKay, Chao Xing, Lu Q. Le

×

Figure 2

MEK inhibitor treatment of pNF decreases ECM deposition.

Options: View larger image (or click on image) Download as PowerPoint
MEK inhibitor treatment of pNF decreases ECM deposition.
(A) Western blo...
(A) Western blots of DRGs extracted from H7;Nf1mut mice, cultured ex vivo, and treated with vehicle (Veh) (n = 3) or MEK inhibitor (MEKi) (n = 3) for 3 days. (B) Volcano plot of the mass spectrometry data set showing P values against fold changes (fc). The red line indicates P value equal to 0.05, and targets above the red line are significantly changed. (C–E) GO analysis showing the top 10 significantly downregulated categories in cellular component (C), molecular function (D), and biological pathway (E) in the MEKi-treated groups compared with vehicle-treated. The left y axis indicates the level of significance of each category. FDR, false discovery rate. The right y axis indicates the number of targets included in each category. (F) Mass spectrometry data analysis of the indicated collagen isoforms based on the abundance ratios. Data are presented as the ratios of MEKi compared with vehicles. Data are shown as means ± SEM. Comparisons among groups were performed by Student’s t test. *P < 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts